GlassScriptPhysician profile
Erin Howard
NPI 1295583045
$866.07
in general payments reported to CMS, 2019-2025
19 companies · $716 in 2025
The $716 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $150 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $866.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $124.61 | 2025 | Korlym |
| Amgen INC. | $107.05 | 2024-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $87.53 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.89 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $78.43 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $57.04 | 2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $55.36 | 2024-2025 | |
| Lilly USA, LLC | $42.34 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Sanofi Pasteur INC. | $29.26 | 2025 | |
| Inspire Medical Systems, INC. | $26.92 | 2024 | Inspire |
| Kowa Pharmaceuticals America, INC. | $25.31 | 2025 | Zoryve |
| Exact Sciences Corporation | $25.18 | 2025 | |
| Axsome Therapeutics, INC. | $21.57 | 2025 | Auvelity |
| Medline Industries LP | $20.11 | 2025 | |
| Apellis Pharmaceuticals, INC. | $19.30 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $18.60 | 2025 | Shingrix, Arexvy |
| Madrigal Pharmaceuticals | $14.99 | 2025 | Rezdiffra |
| Ibsa Pharma INC. | $14.43 | 2025 | Tirosint, Flector, Licart |
| Currax Pharmaceuticals LLC | $14.15 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.